EUVIMEDEUVIMED entdecken
Crossref

Designing Chromane Derivatives as α 2A -Adrenoceptor Selective Agonists via Conformation Constraint

Xucheng Lv, Peilan Zhou, Xuehong Qiao, Yulei Li, Xingxing Yang, Jiaqi Wang, Xinhua He iD, Ruibin Su

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xucheng Lv und 7 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Pharmacology and Toxicology, Haidian District, Beijing 100850, China. Hauptthemen laut MEDLINE: Adrenergic alpha-2 Receptor Agonists, Chromans, Drug Design, Receptors, Adrenergic, alpha-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhancing the selectivity of alpha2-adrenoceptor (α2A-AR) agonists remains an unresolved issue. Herein, we reported the design of an α2A-AR agonist using the conformation constraint method, beginning with medetomidine. The structure-activity relationship indicated that the 8-substituent of chromane derivatives exerted the most pronounced effect on α2A-AR agonistic activity. Compounds A9 and B9 were identified as the most promising, exhibiting EC50 values of 0.78 and 0.23 nM, respectively. Their selectivity indexes surpassed dexmedetomidine (DMED) by 10-80 fold. In vivo studies demonstrated that both A9 and B9 dose-dependently increased the loss of righting reflex in mice, with ED50 values of 1.54 and 0.138 mg/kg, respectively. Binding mode calculations and mutation studies suggested the indispensability of the hydrogen bond between ASP1283.32 and α2A-AR agonist. In particular, A9 and B9 showed no dual reverse pharmacological effect, a characteristic exhibited by DMED in α2A-AR activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic alpha-2 Receptor AgonistsChromansDrug DesignReceptors, Adrenergic, alpha-2AnimalsHumansMaleMiceMolecular ConformationMolecular Docking SimulationStructure-Activity Relationship

Substanzen

Adrenergic alpha-2 Receptor AgonistsChromansReceptors, Adrenergic, alpha-2

Autor:innen und Institutionen

  • Beijing Institute of Pharmacology and Toxicology, Haidian District, Beijing 100850, China.
  • Shenyang Pharmaceutical University, Shenyang 110016, China.

ORCID-Profile: Xinhua He

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lv, X., Zhou, P., Qiao, X., Li, Y., Yang, X., Wang, J., He, X., & Su, R. (2024). Designing Chromane Derivatives as α 2A -Adrenoceptor Selective Agonists via Conformation Constraint. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01239

Vancouver

Lv X, Zhou P, Qiao X, Li Y, Yang X, Wang J, et al. Designing Chromane Derivatives as α 2A -Adrenoceptor Selective Agonists via Conformation Constraint. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01239

BibTeX
@article{Lv2024,
  author = {Lv, Xucheng and Zhou, Peilan and Qiao, Xuehong and Li, Yulei and Yang, Xingxing and Wang, Jiaqi and He, Xinhua and Su, Ruibin},
  title = {Designing Chromane Derivatives as α 2A -Adrenoceptor Selective Agonists via Conformation Constraint},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01239}
}
Kostenlos starten →